Category Archives: MS Treatment

[author: Michael Qian] The Supreme Court is abuzz, kicking off a new term this morning and announcing several cert grants last week. Things have been calmer across town at the Federal Circuitwhich, unlike the Supreme Court, has been working all summer. Continue reading →

CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive, a multimedia platform dedicated to providing health care professionals who treat neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, in partnership with the Consortium of Multiple Sclerosis Centers (CMSC), is pleased to announce two upcoming webcast programs on multiple sclerosis (MS) in October. Our partnership with CMSC is leading to extremely important education for neurology professionals everywhere, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of NeurologyLive. Through these programs, attendees will get expert perspectives on hot topics in MS that will lead to improved patient care and outcomes Continue reading →

Oct. 8, 2020 05:00 UTC PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 12 abstracts during the 11th World Congress for Neurorehabilitation (WCNR), taking place virtually between 7-11 October 2020.1-13 Spasticity is a disabling condition in adults and children, characterized by velocity-dependent muscle hyperactivity Continue reading →

ENGLEWOOD Englewood community leader Gwen Johnson is on the road to recovery more than five months after contracting coronavirus. Johnson, known as Ms. Gwen to people in the neighborhood, was diagnosed with COVID-19 in early April Continue reading →

Doctors believe they are closer to a treatment for multiple sclerosis after discovering a drug that repairs the coatings around nerves that are damaged by the disease. A clinical trial of the cancer drug bexarotene showed that it repaired the protective myelin sheaths that MS destroys Continue reading →

In patients with active relapses during secondary progressive multiple sclerosis (SPMS), treatment with disease-modifying therapies (DMTs) may slow the rate of disability accumulation, according to study results published in JAMA Neurology. Additionally, the study findings indicated that the rate of disability progression following disease onset was not dependent on early disease course/treatment. There is limited data available regarding the association of relapses and DMTs with the rate of disability accumulation in patients with SPMS. Continue reading →

NORTH CHICAGO, Ill., Sept. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury. Continue reading →

Sept. 27, 2020 7:00 am ET Community members in the Khayelitsha township in Cape Town, South Africa, work to rebuild their homes. Amid the coronavirus, police are tearing down shacks built on public land by people who can no longer pay rent on their previous homes Continue reading →

Newswise Background: Coronavirus disease 19 (COVID-19) is the most globally impactful pandemic of the past century. The causative pathogen, SARS-CoV-2, infects ACE2-expressing cells and leads to pulmonary disease and a systemic immune response. Continue reading →

A new business intelligence report released by Data Bridge Market Research with title Global Multiple Sclerosis Market are taken from trustworthy sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts. Market research report is always helpful to business or organization in every subject of trade for taking better decisions, solving the toughest business questions and minimizing the risk of failure. Continue reading →